Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Namilumab in moderate-to-severely active axial spondyloarthritis
NCT03622658Phase 2Completed
- Sponsor
- Izana Bioscience
- Start
- Sep 2018
- Primary completion
- Feb 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of namilumab in axial spondyloarthritis (axSpA), sponsored by Izana Bioscience. Started Sep 2018; status: completed.
02
Drugs
namilumab
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NCT03622658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03622658.